Cargando…
Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients
BACKGROUND: Because of previous ventricular arrhythmia (VA) episodes, patients with implantable cardioverter-defibrillator (ICD) for secondary prevention (SP) are generally considered to have a higher burden of VAs than primary prevention (PP) patients. However, when PP patients experienced VA, the...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805511/ https://www.ncbi.nlm.nih.gov/pubmed/31638918 http://dx.doi.org/10.1186/s12872-019-1218-9 |
_version_ | 1783461402543915008 |
---|---|
author | Zhou, You Zhao, Shuang Chen, Keping Hua, Wei Su, Yangang Chen, Silin Liang, Zhaoguang Xu, Wei Zhang, Shu |
author_facet | Zhou, You Zhao, Shuang Chen, Keping Hua, Wei Su, Yangang Chen, Silin Liang, Zhaoguang Xu, Wei Zhang, Shu |
author_sort | Zhou, You |
collection | PubMed |
description | BACKGROUND: Because of previous ventricular arrhythmia (VA) episodes, patients with implantable cardioverter-defibrillator (ICD) for secondary prevention (SP) are generally considered to have a higher burden of VAs than primary prevention (PP) patients. However, when PP patients experienced VA, the difference in the prognosis of these two patient groups was unknown. METHODS: The clinical characteristics and follow-up data of 835 ICD patients (364 SP patients and 471 PP patients) with home monitoring feature were retrospectively analysed. The incidence rate and risk of subsequent VA and all-cause mortality were compared between PP patients after the first appropriate ICD therapy and SP patients. RESULTS: During a mean follow-up of 44.72 ± 20.87 months, 210 (44.59%) PP patients underwent appropriate ICD therapy. In the Kaplan-Meier survival analysis, the PP patients after appropriate ICD therapy were more prone to VA recurrence and all-cause mortality than SP patients (P<0.001 for both endpoints). The rate of appropriate ICD therapy and all-cause mortality in PP patients after the first appropriate ICD therapy was significantly higher than that in SP patients (for device therapy, 59.46 vs 20.64 patients per 100 patient-years; incidence rate ratio [IRR] 2.880, 95% confidence interval [CI]: 2.305–3.599; P<0.001; for all-cause mortality, 14.08 vs 5.40 deaths per 100 patient-years; IRR 2.607, 95% CI: 1.884–3.606; P<0.001). After propensity score matching for baseline characteristics, the risk of VA recurrence in PP patients with appropriate ICD therapy was still higher than that in SP patients (41.80 vs 19.10 patients per 100 patient-years; IRR 2.491, 95% CI: 1.889–3.287; P<0.001), but all-cause mortality rates were similar between the two groups (12.61 vs 9.33 deaths per 100 patient-years; IRR 1.352, 95% CI: 0.927–1.972; P = 0.117). CONCLUSIONS: Once PP patients undergo appropriate ICD therapy, they will be more prone to VA recurrence and death than SP patients. |
format | Online Article Text |
id | pubmed-6805511 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68055112019-10-24 Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients Zhou, You Zhao, Shuang Chen, Keping Hua, Wei Su, Yangang Chen, Silin Liang, Zhaoguang Xu, Wei Zhang, Shu BMC Cardiovasc Disord Research Article BACKGROUND: Because of previous ventricular arrhythmia (VA) episodes, patients with implantable cardioverter-defibrillator (ICD) for secondary prevention (SP) are generally considered to have a higher burden of VAs than primary prevention (PP) patients. However, when PP patients experienced VA, the difference in the prognosis of these two patient groups was unknown. METHODS: The clinical characteristics and follow-up data of 835 ICD patients (364 SP patients and 471 PP patients) with home monitoring feature were retrospectively analysed. The incidence rate and risk of subsequent VA and all-cause mortality were compared between PP patients after the first appropriate ICD therapy and SP patients. RESULTS: During a mean follow-up of 44.72 ± 20.87 months, 210 (44.59%) PP patients underwent appropriate ICD therapy. In the Kaplan-Meier survival analysis, the PP patients after appropriate ICD therapy were more prone to VA recurrence and all-cause mortality than SP patients (P<0.001 for both endpoints). The rate of appropriate ICD therapy and all-cause mortality in PP patients after the first appropriate ICD therapy was significantly higher than that in SP patients (for device therapy, 59.46 vs 20.64 patients per 100 patient-years; incidence rate ratio [IRR] 2.880, 95% confidence interval [CI]: 2.305–3.599; P<0.001; for all-cause mortality, 14.08 vs 5.40 deaths per 100 patient-years; IRR 2.607, 95% CI: 1.884–3.606; P<0.001). After propensity score matching for baseline characteristics, the risk of VA recurrence in PP patients with appropriate ICD therapy was still higher than that in SP patients (41.80 vs 19.10 patients per 100 patient-years; IRR 2.491, 95% CI: 1.889–3.287; P<0.001), but all-cause mortality rates were similar between the two groups (12.61 vs 9.33 deaths per 100 patient-years; IRR 1.352, 95% CI: 0.927–1.972; P = 0.117). CONCLUSIONS: Once PP patients undergo appropriate ICD therapy, they will be more prone to VA recurrence and death than SP patients. BioMed Central 2019-10-21 /pmc/articles/PMC6805511/ /pubmed/31638918 http://dx.doi.org/10.1186/s12872-019-1218-9 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Zhou, You Zhao, Shuang Chen, Keping Hua, Wei Su, Yangang Chen, Silin Liang, Zhaoguang Xu, Wei Zhang, Shu Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients |
title | Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients |
title_full | Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients |
title_fullStr | Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients |
title_full_unstemmed | Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients |
title_short | Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients |
title_sort | risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6805511/ https://www.ncbi.nlm.nih.gov/pubmed/31638918 http://dx.doi.org/10.1186/s12872-019-1218-9 |
work_keys_str_mv | AT zhouyou riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients AT zhaoshuang riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients AT chenkeping riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients AT huawei riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients AT suyangang riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients AT chensilin riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients AT liangzhaoguang riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients AT xuwei riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients AT zhangshu riskofsubsequentventriculararrhythmiaishigherinprimarypreventionpatientswithimplantablecardioverterdefibrillatorthaninsecondarypreventionpatients |